<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.ajmc.com/view/fda-approves-oral-giredestrant-regimen-for-esr1-mutated-breast-cancer</loc>
      <lastmod>2026-11-18T17:51:13.156Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:51:13.156Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/sending-the-call-for-fixed-duration-bispecific-trials-in-myeloma</loc>
      <lastmod>2026-11-18T17:37:46.308Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:37:46.308Z</news:publication_date>
        <news:title><![CDATA[Sending the Call for Fixed-Duration Bispecific Trials in Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/hepatitis-b-screening-gaps-persist-as-functional-cure-option-arrives</loc>
      <lastmod>2026-11-18T17:01:12.795Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:01:12.795Z</news:publication_date>
        <news:title><![CDATA[Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/dazodalibep-shows-phase-3-benefit-in-sj-gren-disease</loc>
      <lastmod>2026-11-18T16:01:41.621Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T16:01:41.621Z</news:publication_date>
        <news:title><![CDATA[Dazodalibep Shows Phase 3 Benefit in Sjögren Disease ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/iga-nephropathy-fsgs-care-needs-coordinators-not-just-new-drugs</loc>
      <lastmod>2026-11-18T15:51:13.252Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:51:13.252Z</news:publication_date>
        <news:title><![CDATA[IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New Drugs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/obstructive-hcm-care-hinges-on-teams-pharmacy-and-drug-access</loc>
      <lastmod>2026-11-18T14:36:55.816Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:36:55.816Z</news:publication_date>
        <news:title><![CDATA[Obstructive HCM Care Hinges on Teams, Pharmacy, and Drug Access ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-approves-secukinumab-as-first-anti-il-17-biologic-for-pmr</loc>
      <lastmod>2026-11-18T14:30:01.007Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:30:01.007Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/mash-drugs-raise-urgency-for-earlier-diagnosis-rohit-loomba-md</loc>
      <lastmod>2026-11-18T14:13:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:13:00Z</news:publication_date>
        <news:title><![CDATA[MASH Drugs Raise Urgency for Earlier Diagnosis: Rohit Loomba, MD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/patient-factors-and-access-barriers-in-extensive-stage-sclc</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Patient Factors and Access Barriers in Extensive-Stage SCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/aatd-pipeline-replacement-liver-directed-rna-and-gene-therapy-approaches</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[AATD Pipeline: Replacement, Liver-Directed, RNA, and Gene Therapy Approaches]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/switching-aatd-patients-to-every-3-4-week-infusions-logistics-and-cost</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Switching AATD Patients to Every 3-4 Week Infusions: Logistics and Cost]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/maintenance-therapy-options-in-extensive-stage-sclc</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Maintenance Therapy Options in Extensive-Stage SCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/atopic-dermatitis-escalation-stalls-on-payer-rules-thin-tracking</loc>
      <lastmod>2026-11-17T21:46:17.823Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:46:17.823Z</news:publication_date>
        <news:title><![CDATA[Atopic Dermatitis Escalation Stalls on Payer Rules, Thin Tracking]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/inebilizumab-isn-t-a-last-resort-in-gmg-richard-j-nowak-md-ms</loc>
      <lastmod>2026-11-17T21:34:01.244Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:34:01.244Z</news:publication_date>
        <news:title><![CDATA[Inebilizumab Isn’t a Last Resort in gMG: Richard J. Nowak, MD, MS]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/real-world-data-support-cemiplimab-efficacy-in-advanced-nsclc</loc>
      <lastmod>2026-11-17T21:30:40.416Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:30:40.416Z</news:publication_date>
        <news:title><![CDATA[Real-World Data Support Cemiplimab Efficacy in Advanced NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-grants-accelerated-approval-to-neladalkib-for-previously-treated-alk-positive-nsclc</loc>
      <lastmod>2026-11-17T21:21:44.032Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:21:44.032Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/emerging-threats-to-cell-and-gene-therapy-access</loc>
      <lastmod>2026-11-17T21:21:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:21:00Z</news:publication_date>
        <news:title><![CDATA[Emerging Threats to Cell and Gene Therapy Access]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/measles-in-pregnancy-and-newborns-lessons-from-canadas-outbreak</loc>
      <lastmod>2026-11-17T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Measles in Pregnancy and Newborns: Lessons From Canada's Outbreak]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-adds-head-to-head-maple-hcm-data-to-aficamten-label-in-ohcm</loc>
      <lastmod>2026-11-17T20:10:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:10:00Z</news:publication_date>
        <news:title><![CDATA[FDA Adds Head-to-Head MAPLE-HCM Data to Aficamten Label in oHCM]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/precision-medicine-equity-hinges-on-systems-but-coverage-gaps-linger</loc>
      <lastmod>2026-11-17T20:00:20.422Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:00:20.422Z</news:publication_date>
        <news:title><![CDATA[Precision Medicine Equity Hinges on Systems, but Coverage Gaps Linger ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/in-psoriasis-il-23-inhibitors-tied-to-lower-psa-risk-than-jaks</loc>
      <lastmod>2026-11-17T19:18:31.281Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T19:18:31.281Z</news:publication_date>
        <news:title><![CDATA[In Psoriasis, IL-23 Inhibitors Tied to Lower PsA Risk Than JAKs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/tirzepatide-lowers-bmi-by-185-in-adolescents-with-obesity</loc>
      <lastmod>2026-11-17T17:50:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:50:00Z</news:publication_date>
        <news:title><![CDATA[Tirzepatide Lowers BMI by 18.5% in Adolescents With Obesity]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/urban-hospital-care-linked-to-better-hfref-outcomes-for-rural-patients</loc>
      <lastmod>2026-11-17T16:23:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:23:00Z</news:publication_date>
        <news:title><![CDATA[Urban Hospital Care Linked to Better HFrEF Outcomes for Rural Patients]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/choosing-among-emerging-systemic-agents-for-vitiligo</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Choosing Among Emerging Systemic Agents for Vitiligo]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/individualizing-third-line-treatment-in-mcrc</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Individualizing Third-Line Treatment in mCRC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/selecting-asthma-patients-for-6-month-il-5-dosing-fit-and-safety</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Selecting Asthma Patients for 6-Month IL-5 Dosing: Fit and Safety]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/braf-v600e-mcrc-targeted-therapy-and-rechallenge-strategies</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[BRAF V600E mCRC: Targeted Therapy and Rechallenge Strategies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/preparing-for-systemic-treatment-options-meeting-the-moment-in-vitiligo</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Preparing for Systemic Treatment Options: Meeting the Moment in Vitiligo]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/glp-1s-alone-won-t-solve-obesity-jama-summit-report-says</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/ultra-long-acting-il-5-inhibition-a-paradigm-shift-in-asthma-care</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Ultra-Long-Acting IL-5 Inhibition: A Paradigm Shift in Asthma Care]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-approves-dexmedetomidine-sublingual-film-as-at-home-agitation-therapy</loc>
      <lastmod>2026-11-16T21:22:52.702Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T21:22:52.702Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/andrew-kuykendall-md-says-rusfertide-could-individualize-pv-care</loc>
      <lastmod>2026-11-16T21:02:39.711Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T21:02:39.711Z</news:publication_date>
        <news:title><![CDATA[Andrew Kuykendall, MD, Says Rusfertide Could Individualize PV Care]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/inebilizumab-works-early-or-late-in-gmg-richard-j-nowak-md-ms</loc>
      <lastmod>2026-11-16T20:10:51.488Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:10:51.488Z</news:publication_date>
        <news:title><![CDATA[Inebilizumab Works Early or Late in gMG: Richard J. Nowak, MD, MS]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/shorter-us-residence-linked-to-greater-crc-screening-nonadherence</loc>
      <lastmod>2026-11-16T20:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:00:00Z</news:publication_date>
        <news:title><![CDATA[Shorter US Residence Linked to Greater CRC Screening Nonadherence]]></news:title>
      </news:news>
	</url></urlset>